VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers (“ATMA”)…

Source

Previous articleBraxia Scientific Announces Board Appointment
Next articlePsyence Group Completes Export of Psilocybin Mushrooms to Canada